Palantir Technologies Inc. NASDAQ: PLTR The shares are supported by their 15-day simple sliding average after the company announced partnership with R1 for launching R37, laboratories controlled by artificial intelligence, focused on improving financial operations in the field of healthcare.
Palantir Technologies Today
Palantir Technologies
As of 03.21.2025 21:00
- 52-week range
- $ 20.33
▼
$ 125.41
- P/e ratio.
- 478.76
- Value is valuable
- $ 74.45
This is the last of the series of new and updated contracts that Palantir has announced over the past 30 days. Each of these contracts adds to the upper line of the company, which is significantly lower than its high rating.
This assessment is why the PLTR shares return to Earth in 2025 after meteoric growth, which began in 2023. Honestly, the shares have still grown by more than 13% per year. This is better than many technological promotions, including from the “magnificent seven”, but in 30 days ending on March 20, 18.9%, ending from fears about a high assessment of the action.
Nevertheless, the deal with R1 may be precisely what the doctor ordered from the point of view of the arrest of reducing prices for shares. Not only is it another victory in the commercial side of the business, but also the steamer positions as a potential solution in the sector that requires transformation.
Solving a difficult problem
The federal government has a lot of talk about waste and inefficiency. Nevertheless, one of the areas in the private sector, which is known for uncontrolled growing costs, is the management of income cycles (RCM). This is a process that each organization, from a doctor’s office to hospitals, uses to manage financial transactions related to setting accounts and collecting income for medical services. These operations include reconciliation of insurance payments, write -offs, adjustments to the contract and, of course, patient payments.
But the problems associated with compensation for healthcare expenses become impossible for ignoring. Suppliers are faced with economic pressure at a time when administrative health costs amount to 40% of the expenses in the US hospital.
R1 is a leader in RCM with proprietary technologies that helps suppliers of medical services to manage costs, increase income and optimize operations. Artificial intelligence becomes a key element in this process, and it is here that the advanced tools of the AI of the AI Palantir enter.
The partnership will see that two companies are developing intellectual solutions for automation to solve emergency compensation problems in healthcare with speed and scale.
In an interview with Bloomberg, the Chief Executive Director of Palantir (General Director) Alex Karp noted: “R1 brings unrivaled ambitions to the health field, which desperately needs this,” said Alex Karp, co-founder and general director of Palantir Technologies. “Introducing our engineers directly in the R1 operation, we can quickly scale intellectual automation and lead to measurable speed on speed, allowing suppliers to focus on ensuring better patient care.”
Palantir Technologies Inc. (PLTR) Private diagram on Saturday, March 22, 2025
Real driver for the future growth of the Palantir Foundation
The steamer is often mixed with memes. This goes back to when the company became public as direct listing in 2020. It was a way that Palantir made its shares available to retail investors who held heavy bags before observing shares in the second half of 2023.
Since then, it was a great trip, but retail investors will not raise the following. Institutions will run. “Smart money” remained far from PLTR shares, while the action was traded less than $ 10. But this became impossible to ignore, even if the assessment is unpleasant for many investors.
This inevitability can be seen in the forecasts of Palantir analysts on Marketbeat, which show that price targets growing are much higher than the consensus, even if the shares were drifted below. While the consensus target price as of March 20 amounted to 74.45 US dollars, which is 14% discount on its closure, many analysts raised target price indicators. And this list is now going beyond the scope of Dan Ives from Wedbush. In fact, Loop Capital, reducing the target price from 141 to 125 dollars, still has a higher price than IVES, which has a target target for shares of $ 120.
Before considering Palantir technologies, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and Palantir Technologies was not on the list.
While Palantir Technologies currently has a decrease in rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
If the company general, COO and financial director of the company sold shares, would you like to know? Marketbeat has just made its list of twelve actions that corporate insiders refuse. Fill in the form below to see which companies compiled the list.
Get this free report